Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Hunan, China.
Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Hunan, China.
Cell Cycle. 2022 Oct;21(20):2121-2131. doi: 10.1080/15384101.2022.2087755. Epub 2022 Jun 14.
Osteosarcoma (OS) is one of the most prevalent and highly aggressive bone malignancies. The treatment strategies of OS is under standard regimens, including surgical resection, chemotherapy, and other adjuvant therapy. However, the 5-year survival rate is still unsatisfactory. Previous studies have demonstrated that the expression of miR-34a decreases in osteosarcoma, which is involved in regulating numerous genes directly or indirectly at the post-transcriptional level and other pathways. Thus, miR-34a plays an important role in mediating OS cell proliferation, differentiation, migration, and apoptosis, and might be a pivotal biomarker for OS with diagnostic and therapeutic potentials. In this review, we aim to summarize the relationship between miR-34a and OS, with an emphasis on the specific mechanisms in OS development referring to miR-34a. Moreover, the potential role of miR-34a as a diagnostic, prognostic, and therapeutic candidate for OS would be presented in detail. However, the molecular mechanisms related to miR-34a and OS remain elusive, and more investigations are needed to reach a comprehensive understanding.
骨肉瘤(OS)是最常见和高度侵袭性的骨恶性肿瘤之一。OS 的治疗策略是在标准方案下进行,包括手术切除、化疗和其他辅助治疗。然而,5 年生存率仍然不尽人意。先前的研究表明,miR-34a 在骨肉瘤中的表达降低,它通过直接或间接的在转录后水平和其他途径来调节众多基因。因此,miR-34a 在介导 OS 细胞增殖、分化、迁移和凋亡方面起着重要作用,可能是具有诊断和治疗潜力的 OS 的关键生物标志物。在这篇综述中,我们旨在总结 miR-34a 与 OS 的关系,并重点介绍 miR-34a 在 OS 发展中的具体机制。此外,还将详细介绍 miR-34a 作为 OS 的诊断、预后和治疗候选物的潜在作用。然而,与 miR-34a 和 OS 相关的分子机制仍不清楚,需要进一步研究以全面了解。
Cancer Biother Radiopharm. 2018-7-10
Cell Death Dis. 2018-7-10
Life (Basel). 2025-7-28
Discov Oncol. 2025-5-13
Diagnostics (Basel). 2025-3-6
Int J Nanomedicine. 2024
J Biomed Sci. 2024-6-5
Cancers (Basel). 2023-9-26
Expert Rev Mol Diagn. 2021-2
Cell Prolif. 2020-8-10
J Cell Physiol. 2020-12
Cell Mol Gastroenterol Hepatol. 2020
J Cell Physiol. 2020-10
J Cancer. 2020-1-13
Biomed Pharmacother. 2020-1-24
Int J Clin Exp Pathol. 2019-8-1